2010300C02Rik Activators encompass a range of chemical compounds that indirectly stimulate the functional activity of 2010300C02Rik through diverse signaling pathways. Forskolin, by bolstering cAMP levels, facilitates the activation of PKA, potentially leading to phosphorylation events that enhance 2010300C02Rik activity. Similarly, Epigallocatechin gallate and Genistein, by inhibiting protein kinases and tyrosine kinases respectively, may reduce negative regulatory influences on pathways in which 2010300C02Rik operates, resulting in its increased activity. Sphingosine-1-phosphate, through its interaction with specific receptors, could initiate signaling cascades that promote 2010300C02Rik's function. PMA, as a PKC activator, and the PI3K inhibitors LY294002 and Wortmannin, might enhance 2010300C02Rik by modifying phosphorylation patterns within the cell that affect its activity. 2010300C02Rik Activators refer to a class of compounds that specifically elevate the activity of the 2010300C02Rik gene. This gene is involved in various cellular mechanisms, and its expression is critical for certain biological processes within mice.
To identify these activators, a meticulous process is undertaken, beginning with high-throughput screening techniques. In these screens, thousands of chemicals are tested for their ability to promote gene expression. The screening process commonly employs a reporter assay system where the promoter of the 2010300C02Rik gene is fused to a reporter gene such as luciferase. The activation of the promoter by a compound results in the expression of luciferase, which can be easily detected due to its luminescent properties. The intensity of light produced correlates with the level of transcriptional activation. Thus, compounds that cause a marked increase in luminescence are selected for subsequent validation as 2010300C02Rik Activators. This phase is critical as it narrows down the pool to those compounds that specifically act on the gene of interest, paving the way for deeper analysis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
This polyphenol inhibits several protein kinases, which could reduce negative regulation on pathways that 2010300C02Rik is a part of, indirectly enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Functions as a ligand for sphingosine-1-phosphate receptors, potentially modulating intracellular signaling cascades that could upregulate the functional activity of 2010300C02Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC), which might lead to the phosphorylation of substrates involved in the same pathway as 2010300C02Rik, thereby enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could shift the balance of downstream signaling pathways, such as AKT, in favor of those that enhance the activity of 2010300C02Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Increases intracellular calcium levels and can activate calcium-dependent signaling pathways that may intersect with those regulated by 2010300C02Rik. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A broad-spectrum kinase inhibitor that could preferentially modulate kinases affecting 2010300C02Rik activity, leading to an indirect enhancement of its function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A potent SERCA pump inhibitor, leading to increased cytosolic calcium and potentially enhancing 2010300C02Rik by activating calcium-dependent pathways that intersect with its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This p38 MAPK inhibitor could redirect signaling towards pathways that upregulate the functional activity of 2010300C02Rik. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
As a tyrosine kinase inhibitor, it may diminish competitive signaling pathways and indirectly augment the pathways that enhance 2010300C02Rik activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, which might shift cellular signaling dynamics to enhance pathways that 2010300C02Rik is part of, leading to its increased functional activity. | ||||||